Morgan Stanley
TRIB

Morgan Stanley’s Trinity Biotech TRIB Stock Holding History

Morgan Stanley’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156 Hold
13
– – ﹤0.01% 7884
2026
Q1 		$218 Sell
13
-6
-32% -$132 ﹤0.01% 7692
2025
Q4 		$459 Buy
19
+3
+19% +$88 ﹤0.01% 7517
2025
Q3 		$499 Buy
+16
New +$504 ﹤0.01% 7495
2025
Q2 		– Sell
-72
Closed -$1.23K – 8275
2025
Q1 		$1.23K Hold
72
– – ﹤0.01% 7256
2024
Q4 		$1.9K Sell
72
-17
-19% -$682 ﹤0.01% 7205
2024
Q3 		$2.93K Hold
89
– – ﹤0.01% 7050
2024
Q2 		$5.67K Sell
89
-8
-8% -$466 ﹤0.01% 6820
2024
Q1 		$5.94K Hold
97
– – ﹤0.01% 6848
2023
Q4 		$6.24K Hold
97
– – ﹤0.01% 6785
2023
Q3 		$10.7K Sell
97
-158
-62% -$19.4K ﹤0.01% 6711
2023
Q2 		$36.4K Hold
255
– – ﹤0.01% 6340
2023
Q1 		$35.9K Sell
255
-4
-2% -$618 ﹤0.01% 6402
2022
Q4 		$38.4K Sell
259
-40
-13% -$7.27K ﹤0.01% 6404
2022
Q3 		$48K Sell
299
-14
-4% -$2.71K ﹤0.01% 6429
2022
Q2 		$57K Sell
313
-406
-56% -$74.4K ﹤0.01% 6551
2022
Q1 		$115K Buy
719
+315
+78% +$54.4K ﹤0.01% 6233
2021
Q4 		$87K Buy
404
+266
+193% +$75.4K ﹤0.01% 6521
2021
Q3 		$45K Buy
138
+39
+39% +$13.7K ﹤0.01% 6771
2021
Q2 		$43K Sell
99
-644
-87% -$321K ﹤0.01% 6733
2021
Q1 		$419K Sell
743
-715
-49% -$516K ﹤0.01% 5248
2020
Q4 		$833K Sell
1,458
-217
-13% -$108K ﹤0.01% 4768
2020
Q3 		$508K Buy
1,675
+398
+31% +$138K ﹤0.01% 4633
2020
Q2 		$417K Buy
1,277
+893
+233% +$204K ﹤0.01% 4695
2020
Q1 		$63K Sell
384
-2,680
-87% -$421K ﹤0.01% 5371
2019
Q4 		$475K Sell
3,064
-8
-0.3% -$1.14K ﹤0.01% 4957
2019
Q3 		$558K Hold
3,072
– – ﹤0.01% 4633
2019
Q2 		$761K Sell
3,072
-30
-1% -$10.7K ﹤0.01% 4381
2019
Q1 		$1.33M Buy
3,102
+2
+0.1% +$825 ﹤0.01% 3911
2018
Q4 		$1.06M Sell
3,100
-6
-0.2% -$2.78K ﹤0.01% 4231
2018
Q3 		$1.86M Sell
3,106
-5
-0.2% -$3.26K ﹤0.01% 4059
2018
Q2 		$2.33M Buy
3,111
+4
+0.1% +$2.89K ﹤0.01% 3925
2018
Q1 		$2.4M Sell
3,107
-4
-0.1% -$3.27K ﹤0.01% 3824
2017
Q4 		$2.38M Buy
3,111
+2,049
+193% +$1.58M ﹤0.01% 3883
2017
Q3 		$894K Buy
1,062
+1,022
+2,555% +$855K ﹤0.01% 4505
2017
Q2 		$35K Sell
40
-1
-2% -$850 ﹤0.01% 5951
2017
Q1 		$37K Sell
41
-7
-15% -$6.57K ﹤0.01% 5919
2016
Q4 		$50K Sell
48
-54
-53% -$55.8K ﹤0.01% 5751
2016
Q3 		$202K Buy
102
+4
+4% +$7.47K ﹤0.01% 5019
2016
Q2 		$166K Sell
98
-82
-46% -$139K ﹤0.01% 5023
2016
Q1 		$315K Sell
180
-11
-6% -$17.5K ﹤0.01% 4703
2015
Q4 		$337K Sell
191
-32
-14% -$56.7K ﹤0.01% 4796
2015
Q3 		$382K Buy
223
+10
+5% +$24.1K ﹤0.01% 4758
2015
Q2 		$578K Buy
213
+45
+27% +$117K ﹤0.01% 4614
2015
Q1 		$485K Sell
168
-65
-28% -$180K ﹤0.01% 4675
2014
Q4 		$612K Sell
233
-75
-24% -$194K ﹤0.01% 4524
2014
Q3 		$845K Sell
308
-248
-45% -$806K ﹤0.01% 4188
2014
Q2 		$1.92M Buy
556
+59
+12% +$210K ﹤0.01% 3515
2014
Q1 		$1.8M Buy
497
+16
+3% +$62.9K ﹤0.01% 3507
2013
Q4 		$1.81M Buy
481
+5
+1% +$18K ﹤0.01% 3455
2013
Q3 		$1.55M Buy
476
+51
+12% +$149K ﹤0.01% 3435
2013
Q2 		$1.07M Buy
+425
New +$1.06M ﹤0.01% 3676

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's TRIB Position: Q2 2026 in Review

Morgan Stanley held its Trinity Biotech (TRIB) position steady in Q2 2026 at 13 shares worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #7884.

Morgan Stanley first reported a position in TRIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.4M in Q1 2018. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Morgan Stanley held 13 shares of Trinity Biotech worth $156 as of Q2 2026.
  • Morgan Stanley left its Trinity Biotech share count unchanged in Q2 2026.
  • Trinity Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7884 holding.
  • Morgan Stanley first reported a position in Trinity Biotech in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Trinity Biotech position peaked at $2.4M in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.